Role of Ovarian Suppression in Early Premenopausal Breast Cancer

The benefit from removing ovaries to control premenopausal breast cancer growth was identified more than 100 years ago. Subsequent identification of estrogen receptor (ER) enabled targeting of this approach. Development of gonadotropin-releasing hormone agonists facilitated a reversible method of ov...

Full description

Saved in:
Bibliographic Details
Published inHematology/oncology clinics of North America Vol. 37; no. 1; p. 79
Main Author Francis, Prudence A
Format Journal Article
LanguageEnglish
Published United States 01.02.2023
Subjects
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Female
Humans
Ovary - pathology
Premenopause
Ovarian suppression
Adjuvant endocrine therapy
Early breast cancer
Estrogen receptor-positive
Online AccessGet more information

Cover

More Information
Summary:The benefit from removing ovaries to control premenopausal breast cancer growth was identified more than 100 years ago. Subsequent identification of estrogen receptor (ER) enabled targeting of this approach. Development of gonadotropin-releasing hormone agonists facilitated a reversible method of ovarian function suppression, suitable for young women with early breast cancer. Clinical trials have established the value of including ovarian suppression to reduce recurrence of ER-positive premenopausal early breast cancer. Ovarian suppression administered with chemotherapy can reduce the risk of premature menopause in ER-negative cancer, and increase the prospect of future pregnancy in premenopausal women, regardless of tumor hormone receptor status.
ISSN:1558-1977
DOI:10.1016/j.hoc.2022.08.006